Skip to main content
. 2017 Aug 2;28(10):2581–2587. doi: 10.1093/annonc/mdx339

Table 4.

Serious AEs occurring in ≥2% of patients in either arm

Serious AEs, n (%) Dacarbazine (n=287) Vemurafenib (n=336)
≥1 serious AE 52 (18) 165 (49)
Squamous cell carcinoma of the skin 2 (<1) 66 (20)
Keratoacanthoma 3 (1) 36 (11)
Basal cell carcinoma 2 (<1) 10 (3)
Malignant melanoma 0 7 (2)

AEs, adverse events.